Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q1 2015 · 10-Q
Revenue$17.37M$17.37M+61,942.9% vs Q1 2014 Net Income$39.66M$39.66MN/M vs Q1 2014 EPS Diluted$1.32$1.32N/M vs Q1 2014 Operating Income-$8,104,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
Free Cash Flowderived-$6,619,000N/M Margins · derivedOperating margin-46.6%+78746.2 pt vs Q1 2014
Net margin228.3%+270714.0 pt vs Q1 2014
ended Mar 31, 2015 · filed May 11, 2015 · 41 d after period end